tivozanib治疗索拉非尼治疗后晚期肾细胞癌患者的疗效:III期交叉研究

2018-04-29 MedSci MedSci原创

Tivozanib是血管内皮生长因子受体1、2和3酪氨酸激酶的选择性抑制剂。这项开放标签交叉临床研究(AV-951-09-902)研究了tivozanib在索拉非尼治疗的II期临床试验TIVO-1中疾病仍有进展的患者中的疗效,比较了tivozanib和索拉非尼治疗晚期肾细胞癌(RCC)患者的有效性及安全性。

Tivozanib血管内皮生长因子受体123酪氨酸激酶的选择性抑制剂。这项开放标签交叉临床研究(AV-951-09-902)研究了tivozanib在索拉非尼治疗的II临床试验TIVO-1中疾病仍有进展的患者中的疗效,比较了tivozanib和索拉非尼治疗晚期肾细胞癌(RCC)患者的有效性及安全性。

参与这项单臂II期研究(TIVO-1)的患者先前被随机分配到索拉非尼组,进展然后交叉给tivozanib。患者在他们最后的索拉非尼剂量后4周内接受tivozanib(口服1.5mg /天)。

交叉患者接受tivozanib中位治疗8个周期。从tivozanib治疗开始,中位无进展生存期为11.0个月(95%置信区间[CI]7.3-12.7),中位总生存期为21.6个月(95CI17.0-27.6)。中位缓解时间分别为15.212.7个月。大约77%的患者出现不良事件,最常见的是高血压26%),其次是腹泻(14%)和疲劳(13%),53%的患者有治疗相关的不良事件,其中24%的患者≥3级。约9%和16%的患者分别因不良事件而剂量减少和剂量中断。总共30%的患者有严重的不良事件,4%有治疗相关的严重不良事件。

这项研究显示了强有力的tivozanib抗肿瘤活性。安全性和耐受性概况是可接受的并且与已确定的tivozanib的不良事件概况一致。


原始出处:

Ana M. Molina et al. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. ejcancer. 2018 94: 87-94. doi.org/10.1016/j.ejca.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1978673, encodeId=e77619e867379, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Mar 08 20:17:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916008, encodeId=49561916008b5, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jul 05 19:17:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674575, encodeId=862316e45754d, content=<a href='/topic/show?id=0a331e495db' target=_blank style='color:#2F92EE;'>#Tivozanib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17495, encryptionId=0a331e495db, topicName=Tivozanib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ba26977626, createdName=gostraight, createdTime=Tue Jun 26 18:17:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441743, encodeId=fece1441e43e3, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Tue May 01 14:17:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594514, encodeId=5021159451471, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue May 01 14:17:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031744, encodeId=9dd71031e44a3, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Apr 30 02:17:00 CST 2018, time=2018-04-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1978673, encodeId=e77619e867379, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Mar 08 20:17:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916008, encodeId=49561916008b5, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jul 05 19:17:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674575, encodeId=862316e45754d, content=<a href='/topic/show?id=0a331e495db' target=_blank style='color:#2F92EE;'>#Tivozanib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17495, encryptionId=0a331e495db, topicName=Tivozanib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ba26977626, createdName=gostraight, createdTime=Tue Jun 26 18:17:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441743, encodeId=fece1441e43e3, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Tue May 01 14:17:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594514, encodeId=5021159451471, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue May 01 14:17:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031744, encodeId=9dd71031e44a3, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Apr 30 02:17:00 CST 2018, time=2018-04-30, status=1, ipAttribution=)]
    2018-07-05 juliusluan78
  3. [GetPortalCommentsPageByObjectIdResponse(id=1978673, encodeId=e77619e867379, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Mar 08 20:17:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916008, encodeId=49561916008b5, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jul 05 19:17:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674575, encodeId=862316e45754d, content=<a href='/topic/show?id=0a331e495db' target=_blank style='color:#2F92EE;'>#Tivozanib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17495, encryptionId=0a331e495db, topicName=Tivozanib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ba26977626, createdName=gostraight, createdTime=Tue Jun 26 18:17:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441743, encodeId=fece1441e43e3, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Tue May 01 14:17:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594514, encodeId=5021159451471, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue May 01 14:17:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031744, encodeId=9dd71031e44a3, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Apr 30 02:17:00 CST 2018, time=2018-04-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1978673, encodeId=e77619e867379, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Mar 08 20:17:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916008, encodeId=49561916008b5, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jul 05 19:17:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674575, encodeId=862316e45754d, content=<a href='/topic/show?id=0a331e495db' target=_blank style='color:#2F92EE;'>#Tivozanib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17495, encryptionId=0a331e495db, topicName=Tivozanib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ba26977626, createdName=gostraight, createdTime=Tue Jun 26 18:17:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441743, encodeId=fece1441e43e3, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Tue May 01 14:17:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594514, encodeId=5021159451471, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue May 01 14:17:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031744, encodeId=9dd71031e44a3, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Apr 30 02:17:00 CST 2018, time=2018-04-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1978673, encodeId=e77619e867379, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Mar 08 20:17:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916008, encodeId=49561916008b5, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jul 05 19:17:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674575, encodeId=862316e45754d, content=<a href='/topic/show?id=0a331e495db' target=_blank style='color:#2F92EE;'>#Tivozanib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17495, encryptionId=0a331e495db, topicName=Tivozanib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ba26977626, createdName=gostraight, createdTime=Tue Jun 26 18:17:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441743, encodeId=fece1441e43e3, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Tue May 01 14:17:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594514, encodeId=5021159451471, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue May 01 14:17:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031744, encodeId=9dd71031e44a3, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Apr 30 02:17:00 CST 2018, time=2018-04-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1978673, encodeId=e77619e867379, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri Mar 08 20:17:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916008, encodeId=49561916008b5, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Thu Jul 05 19:17:00 CST 2018, time=2018-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674575, encodeId=862316e45754d, content=<a href='/topic/show?id=0a331e495db' target=_blank style='color:#2F92EE;'>#Tivozanib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17495, encryptionId=0a331e495db, topicName=Tivozanib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8ba26977626, createdName=gostraight, createdTime=Tue Jun 26 18:17:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441743, encodeId=fece1441e43e3, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59875, encryptionId=09a6598e57a, topicName=晚期肾细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87304889998, createdName=12498c24m70暂无昵称, createdTime=Tue May 01 14:17:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594514, encodeId=5021159451471, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue May 01 14:17:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031744, encodeId=9dd71031e44a3, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Apr 30 02:17:00 CST 2018, time=2018-04-30, status=1, ipAttribution=)]
    2018-04-30 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

Brit J Cancer:透明细胞转移性肾细胞癌中,转移性和原发肿瘤基因组背景研究

原发透明细胞肾细胞癌(ccRCC)的基因组背景已经有详细的阐释。然而,关于群体基因组变异(GA)背景在ccRCC转移中的情况所知甚少,或者说与原发性肿瘤在总体上的基因组背景差异情况。研究人员认为,转移性肿瘤的基因组背景也许具有生物学、临床和治疗应用。研究主要运用了二代测序技术。群体1(n=578)包括了348个原发性肿瘤案例和229个转移性肿瘤案例。总的来讲,转移性肿瘤中最为常见的变异为VHL (

CLIN CANCER RES:Pembrolizumab联合聚乙二醇干扰素或Ipilimumab治疗晚期黑色素瘤或肾细胞癌

Pembrolizumab单药,Ipilimumab单药或聚乙二醇干扰素(PEG-IFN)单药对黑色素瘤和肾细胞癌均有抗肿瘤活性。CLIN CANCER RES近期发表了一篇文章,研究Pembrolizumab联合Ipilimumab或PEG-IFN对晚期黑色素瘤或肾细胞癌的抗肿瘤活性。

Brit J Cancer:在晚期肾细胞癌中,卡博替尼和依维莫司药物治疗的总生存长期跟踪调查研究

在阶段3 METEOR试验中(NCT01865747)的抗血管生成治疗之后,与依维莫司药物相比,卡博替尼在晚期肾细胞癌(RCC)患者中能够显著提高无进展自由生存、总生存和客观反映率。在320例记录死亡的第二个中间分析中,研究人员观察到了在总生存方面的显著提升。最近,有研究人员将患有晚期RCC的658名且至少接受1种VEGFR 酪氨酸激酶抑制剂治疗的患者随机分成2个小组,即卡博替尼组(60mg每天)

Oncogene:TGFBR3/β蛋白聚糖表达的减少可以增强肾肿瘤细胞的代谢能力

TGF-β能够调控各种类型癌症细胞的肿瘤形成和迁移能力。然而,在透明细胞肾细胞癌中(ccRCC),TGF-β信号组分的丢失是怎样影响这些能力的机制仍旧不清楚。最近,有研究人员调查了TGFBR3(TGF-β类型III受体,即β蛋白聚糖)在ccRCC中的作用和角色。数据分析表明,TGFBR3在ccRCC组织中表达减少,这与在病人中不良的预后相关。利用免疫低下小鼠的原位接种试验表明,TGFBR3在ccR

Lancet oncol:阿西替尼联合派姆单抗治疗晚期肾细胞癌患者的安全性和效果

既往将PD-1抑制剂与VEGF信号通路酪氨酸激酶抑制剂结合的研究,特点是毒性过大,阻碍进一步发展。现研究人员推出一种比之前检验的更为选择性的VEGF抑制剂——阿西替尼(axitinib),或许可与派姆单抗(抗-PD-1)安全结合,可用于治疗晚期肾细胞癌。研究人员在美国的10个中心进行一尚未结束的、开放性的1b期研究,招募年满18岁的原发病灶已切除的晚期肾细胞癌患者,要求受试者至少有一个可测量的病灶

Sci Rep:利用基因表达对透明细胞肾细胞癌的个性化药物重新定位研究

癌症基因表达的逆转能够预测治疗方法的潜力,并且可以为已经存在的药物发现新的应用方法(药物重新定位)。基因表达逆转潜力在几乎所有的研究中都进行了估算,方法是通过预先将所有肿瘤样本聚集到单一组标签中或者有限的几个分子亚型组标签中。最近,有研究人员调查了是否基于个性化的肿瘤样本基因表达特征的药物重新定位能够优于肿瘤组和亚型组标签药物的使用。研究人员利用来自于530名透明细胞肾细胞癌(ccRCC)患者的5